| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
|
Öberg, K.
|
|
|
31 |
2 |
p. 202-212
|
article
|
| 2 |
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
✰
|
Bjelic-Radisic, V.
|
|
|
31 |
2 |
p. 283-288
|
article
|
| 3 |
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected
|
Connell, C.
|
|
|
31 |
2 |
p. 161-162
|
article
|
| 4 |
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
|
Sternberg, C.N.
|
|
|
31 |
2 |
p. 257-265
|
article
|
| 5 |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
André, T.
|
|
|
31 |
2 |
p. 246-256
|
article
|
| 6 |
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
|
Moehler, M.
|
|
|
31 |
2 |
p. 228-235
|
article
|
| 7 |
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma
|
Lukovic, J.
|
|
|
31 |
2 |
p. 295-301
|
article
|
| 8 |
Editorial Board
|
|
|
|
31 |
2 |
p. iii
|
article
|
| 9 |
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
|
Pros, E.
|
|
|
31 |
2 |
p. 274-282
|
article
|
| 10 |
Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma
|
Zhai, H.
|
|
|
31 |
2 |
p. 169-170
|
article
|
| 11 |
Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature
|
Kalliala, I.
|
|
|
31 |
2 |
p. 213-227
|
article
|
| 12 |
Inconsistencies in currently used definitions of sarcopenia in oncology
|
Taguchi, S.
|
|
|
31 |
2 |
p. 318-319
|
article
|
| 13 |
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
|
Curigliano, G.
|
|
|
31 |
2 |
p. 171-190
|
article
|
| 14 |
Metabolic response assessment and PET-guided treatment of esophageal cancer
|
Lordick, F.
|
|
|
31 |
2 |
p. 163-164
|
article
|
| 15 |
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
|
Zhao, X.
|
|
|
31 |
2 |
p. 302-309
|
article
|
| 16 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park, K.
|
|
|
31 |
2 |
p. 191-201
|
article
|
| 17 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial
|
Barbour, A.P.
|
|
|
31 |
2 |
p. 236-245
|
article
|
| 18 |
Radium and targeted alpha therapy in prostate cancer: new data and concepts
|
Sartor, O.
|
|
|
31 |
2 |
p. 165-166
|
article
|
| 19 |
Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
|
Guzek, A.
|
|
|
31 |
2 |
p. 319-321
|
article
|
| 20 |
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
|
Mansfield, A.S.
|
|
|
31 |
2 |
p. 310-317
|
article
|
| 21 |
Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models
|
Ny, L.
|
|
|
31 |
2 |
p. 266-273
|
article
|
| 22 |
Table of Contents
|
|
|
|
31 |
2 |
p. i-ii
|
article
|
| 23 |
Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles
|
Helleday, T.
|
|
|
31 |
2 |
p. 167-168
|
article
|
| 24 |
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
|
Mazieres, J.
|
|
|
31 |
2 |
p. 289-294
|
article
|
Journal description